Literature DB >> 24835880

A review of international biobanks and networks: success factors and key benchmarks.

Jim Vaught1, Andrea Kelly, Robert Hewitt.   

Abstract

Biobanks and biobanking networks are involved in varying degrees in the collection, processing, storage, and dissemination of biological specimens. This review outlines the approaches that 16 of the largest biobanks and biobanking networks in Europe, North America, Australia, and Asia have taken to collecting and distributing human research specimens and managing scientific initiatives while covering operating costs. Many are small operations that exist as either a single or a few freezers in a research laboratory, hospital clinical laboratory, or pathology suite. Larger academic and commercial biobanks operate to support large clinical and epidemiological studies. Operational and business models depend on the medical and research missions of their institutions and home countries. Some national biobanks operate with a centralized physical biobank that accepts samples from multiple locations. Others operate under a "federated" model where each institution maintains its own collections but agrees to list them on a central shared database. Some collections are "project-driven" meaning that specimens are collected and distributed to answer specific research questions. "General" collections are those that exist to establish a reference collection, that is, not to meet particular research goals but to be available to respond to multiple requests for an assortment of research uses. These individual and networked biobanking systems operate under a variety of business models, usually incorporating some form of partial cost recovery, while requiring at least partial public or government funding. Each has a well-defined biospecimen-access policy in place that specifies requirements that must be met-such as ethical clearance and the expertise to perform the proposed experiments-to obtain samples for research. The success of all of these biobanking models depends on a variety of factors including well-defined goals, a solid business plan, and specimen collections that are developed according to strict quality and operational controls.

Entities:  

Year:  2010        PMID: 24835880      PMCID: PMC4046743          DOI: 10.1089/bio.2010.0003

Source DB:  PubMed          Journal:  Biopreserv Biobank        ISSN: 1947-5543            Impact factor:   2.300


  30 in total

1.  Biospecimens and biorepositories: from afterthought to science.

Authors:  Jimmie B Vaught; Marianne K Henderson; Carolyn C Compton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02       Impact factor: 4.254

2.  Realizing Our Potential in Biobanking: Disease Advocacy Organizations Enliven Translational Research.

Authors:  Kelly A Edwards; Sharon F Terry; Dana Gold; Elizabeth J Horn; Mary Schwartz; Molly Stuart; Suzanne D Vernon
Journal:  Biopreserv Biobank       Date:  2016-04-08       Impact factor: 2.300

Review 3.  Biobanking residual tissues.

Authors:  Peter H J Riegman; Evert-Ben van Veen
Journal:  Hum Genet       Date:  2011-08-04       Impact factor: 4.132

4.  The biobank at the University of Texas Health Science Center at Houston.

Authors:  Jennifer E Sanner; Krystle J Nomie
Journal:  Biopreserv Biobank       Date:  2015-06       Impact factor: 2.300

5.  Assessing Researcher Needs for a Virtual Biobank.

Authors:  Jenna van Draanen; Pamela Davidson; Helene Bour-Jordan; LeeAnna Bowman-Carpio; David Boyle; Steve Dubinett; Brian Gardner; Jachael Gardner; Courtney McFall; Dan Mercola; Terry Nakazono; Stephanie Soares; Hubert Stoppler; Margaret Tempero; Scott Vandenberg; Yu Jui Wan; Sarah Dry
Journal:  Biopreserv Biobank       Date:  2016-12-08       Impact factor: 2.300

Review 6.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 7.  Development and progress of Ireland's biobank network: Ethical, legal, and social implications (ELSI), standardized documentation, sample and data release, and international perspective.

Authors:  Blanaid Mee; Eoin Gaffney; Sharon A Glynn; Simona Donatello; Paul Carroll; Elizabeth Connolly; Sarah Mc Garrigle; Terry Boyle; Delia Flannery; Francis J Sullivan; Paul McCormick; Mairead Griffin; Cian Muldoon; Joanna Fay; Tony O'Grady; Elaine Kay; Joe Eustace; Louise Burke; Asim A Sheikh; Stephen Finn; Richard Flavin; Francis J Giles
Journal:  Biopreserv Biobank       Date:  2013-02       Impact factor: 2.300

Review 8.  Challenges of biobanking in South Africa to facilitate indigenous research in an environment burdened with human immunodeficiency virus, tuberculosis, and emerging noncommunicable diseases.

Authors:  Akin Abayomi; Alan Christoffels; Ravnit Grewal; Locunda A Karam; Catherine Rossouw; Ciara Staunton; Carmen Swanepoel; Beverley van Rooyen
Journal:  Biopreserv Biobank       Date:  2013-11-22       Impact factor: 2.300

9.  Trends in Biobanking Business Planning: Initial Results of a Survey of Biobankers.

Authors:  Daniel Simeon-Dubach; Kirstin Goldring; Marianne K Henderson
Journal:  Biopreserv Biobank       Date:  2016-12-12       Impact factor: 2.300

Review 10.  Before you analyze a human specimen, think quality, variability, and bias.

Authors:  Mark David Lim; Anthony Dickherber; Carolyn C Compton
Journal:  Anal Chem       Date:  2010-11-29       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.